BioNotebook: Second Genome/Pfizer, Merck/Agenus, Endo/Somar, Parion/Gilead, Lightstone Ventures, Kite Pharma, five IPO updates
This article was originally published in Scrip
Second Genome, Pfizer research microbiome; Deal or no deal – Merck/Agenus, Endo/Somar, Parion/Gilead begin, end relationships; Lightstone initiates new VC fund; Kite Pharma raises private cash; and GlobeImmune, Mapi-Pharma, Scynexis, Aldeyra, Ambrx move toward IPOs.
You may also be interested in...
Second quarter venture capital investment in biotech fell from the same period a year ago, but the total remains near record levels, since some early-stage companies have been able to raise big VC sums.
Scrip's second full day of meetings and events during the annual BIO International Convention delivered diverse insights about including patients in drug development, sharing risk with CROs, microbiome-targeting therapies, and the benefits of incubating early-stage technology.
Public company valuations continue to slide as stock market investors shift priorities, but private biotechnology firms are attracting near record-breaking levels of venture capital with one pretty important caveat: More money is being invested in fewer US companies, especially at the earliest stages of business formation.